Lingzhi Tao
Shenzhen, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Application of serum miRNA panel in bladder cancer detection.
Journal: Translational andrology and urology
Published: August 11, 2025
Testing the accuracy of a three-miRNA panel for the detection of primary prostate cancer: a discovery and validation study.
Journal: Future oncology (London, England)
Published: June 06, 2025
Chemoresistance mitigation of dual drug-loaded nanoparticles with doxorubicin and curcumin.
Journal: Cytotechnology
Published: May 14, 2025
A panel of three serum microRNAs as a potential diagnostic biomarker for renal cell carcinoma.
Journal: Scientific reports
Published: February 27, 2025
Panel containing three serum microRNAs: a promising biomarker for early detection of bladder cancer.
Panel containing three serum microRNAs: a promising biomarker for early detection of bladder cancer.
Journal: Frontiers in oncology
Published: July 25, 2024
Testing the accuracy of a four serum microRNA panel for the detection of primary bladder cancer: a discovery and validation study.
Journal: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
Published: May 20, 2024
The value of a panel of circulating microRNAs in screening prostate cancer.
Journal: Translational cancer research
Published: July 25, 2023
Profiling of Serum miRNAs Constructs a Diagnostic 3-miRNA Panel for Clear-Cell Renal Cell Carcinoma.
Profiling of Serum miRNAs Constructs a Diagnostic 3-miRNA Panel for Clear-Cell Renal Cell Carcinoma.
Journal: Clinical genitourinary cancer
Published: January 30, 2023
A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis.
Journal: Frontiers in oncology
Published: October 21, 2022
Bladder cancer diagnosis with a four-miRNA panel in serum.
Journal: Future oncology (London, England)
Published: September 01, 2022
A Four-MicroRNA Panel in Serum as a Potential Biomarker for Screening Renal Cell Carcinoma.
Journal: Frontiers in genetics
Published: March 16, 2022
MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 03, 2018
Last Updated: 09/26/2026